Cogent Biosciences, Inc. (COGT) /
The cash flow of Cogent Biosciences, Inc. over the past 9 years
Chart Cogent Biosciences, Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2017–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Cogent Biosciences, Inc.'s operating cash flow was -$264.44M and its capital expenditures $1.55M, leaving free cash flow of -$266M. Free cash flow was below zero in all 8 years shown. It ranged from -$266M in fiscal 2025 to -$26.75M in fiscal 2017. Capital expenditures were highest in fiscal 2022, at $6.86M. No free cash flow figure is on file for fiscal 2020.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$264.44M | $1.55M | -$266M |
| 2024ended Dec 31, 2024 | -$207.79M | $573K | -$208.36M |
| 2023ended Dec 31, 2023 | -$153.62M | $2.8M | -$156.42M |
| 2022ended Dec 31, 2022 | -$118.64M | $6.86M | -$125.5M |
| 2021ended Dec 31, 2021 | -$58.76M | $1.72M | -$60.48M |
| 2020ended Dec 31, 2020 | -$35.85M | — | — |
| 2019ended Dec 31, 2019 | -$41.51M | $33K | -$41.55M |
| 2018ended Dec 31, 2018 | -$32.49M | $549K | -$33.04M |
| 2017ended Dec 31, 2017 | -$25.84M | $912K | -$26.75M |
Fiscal years as Cogent Biosciences, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Cogent Biosciences, Inc.
- The revenue of Cogent Biosciences, Inc.
- The profitability of Cogent Biosciences, Inc.
- The debt of Cogent Biosciences, Inc.
- All of Cogent Biosciences, Inc.'s financials, charted
Companies of a similar size
- RITMRithm Capital Corp.
- IBPInstalled Building Products, Inc.
- AMTMAmentum Holdings, Inc.
- PSNParsons Corporation
- PECOPhillips Edison & Company, Inc.
Not investment advice. This page shows what Cogent Biosciences, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.